| 30th Apr 2021 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 30th Apr 2021 4:35 pm |
RNS |
Price Monitoring Extension |
| 29th Apr 2021 7:00 am |
RNS |
Phase II Registration Study of HMPL-689 Initiated |
| 28th Apr 2021 2:20 pm |
RNS |
Result of AGM |
| 23rd Apr 2021 7:00 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 14th Apr 2021 10:30 am |
RNS |
Notification of Dilution of Voting Rights |
| 8th Apr 2021 8:30 am |
RNS |
$100m Investment by Baring Private Equity Asia |
| 31st Mar 2021 7:00 am |
RNS |
Total Voting Rights |
| 29th Mar 2021 9:30 am |
RNS |
Grant of LTIP Awards and Share Options |
| 29th Mar 2021 7:00 am |
RNS |
Initiates International Phase I Trials of HMPL-306 |
| 26th Mar 2021 7:00 am |
RNS |
Annual Financial Report |
| 24th Mar 2021 1:30 pm |
RNS |
Agreement to Divest Non-Core OTC Joint Venture |
| 24th Mar 2021 7:00 am |
RNS |
Phase Ib/II Trial of Surufatinib with Tislelizumab |
| 10th Mar 2021 7:00 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 4th Mar 2021 3:15 pm |
RNS |
Publication of Form 20-F |
| 4th Mar 2021 12:00 pm |
RNS |
Final Results, Business Update and Name Change |
| 3rd Feb 2021 7:00 am |
RNS |
Notice of Results |
| 14th Jan 2021 10:00 am |
RNS |
Savolitinib Data to be Presented at Virtual WCLC |
| 11th Jan 2021 7:00 am |
RNS |
Chi-Med & Inmagene Announce Strategic Partnership |
| 31st Dec 2020 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 31st Dec 2020 7:00 am |
RNS |
Total Voting Rights |
| 30th Dec 2020 12:00 pm |
RNS |
NMPA approval of Surufatinib in China for ep-NET |
| 29th Dec 2020 7:45 am |
RNS |
US NDA Rolling Submission of Surufatinib Initiated |
| 22nd Dec 2020 7:00 am |
RNS |
Chi-Med to Present at JPM |
| 15th Dec 2020 9:45 am |
RNS |
Grant of Share Options under Share Option Scheme |
| 30th Nov 2020 7:00 am |
RNS |
Total Voting Rights |
| 27th Nov 2020 7:00 am |
RNS |
Notification of Dilution of Voting Rights |
| 17th Nov 2020 7:00 am |
RNS |
US$100m Equity Investment by CPP Investments |
| 5th Nov 2020 9:00 am |
RNS |
Chi-Med to Present HMPL-689 Clinical Data at ASH |
| 30th Oct 2020 12:00 pm |
RNS |
Chi-Med to Attend Upcoming Conferences |
| 30th Oct 2020 7:00 am |
RNS |
Total Voting Rights |
| 30th Sep 2020 7:00 am |
RNS |
Total Voting Rights |
| 21st Sep 2020 7:00 am |
RNS |
Surufatinib Data at ESMO and in Lancet Oncology |
| 17th Sep 2020 11:45 am |
RNS |
Second Chinese NDA Acceptance for Surufatinib |
| 4th Sep 2020 7:00 am |
RNS |
Chi-Med Initiates Global Phase III Trial |
| 3rd Sep 2020 7:00 am |
RNS |
Chi-Med Initiates a Phase II Trial |
| 28th Aug 2020 11:30 am |
RNS |
Total Voting Rights |
| 24th Aug 2020 7:00 am |
RNS |
Clinical Data to be Presented at ESMO 2020 |
| 12th Aug 2020 10:30 am |
RNS |
Grant of Share Options under Share Option Scheme |
| 10th Aug 2020 7:00 am |
RNS |
Surufatinib Marketing Authorization Application |
